QUALITY ASSURANCE IN MAMMOGRAPHY SCREENING

European Commission Directorate-General For Employment Social Affairs And Inclusion

Sujets

• Health care system
• Cancer
• Physical examination
• Medical diagnosis
• Preventive medicine
• Medical research
• Computer networking
• Data collection
• Program evaluation
• Sociologie, société et politique

Informations

• Publié par: EUROPEAN-COMMISSION-DIRECTORATE-GENERAL-FOR-EMPLOYMENT_SOCIAL-AFFAIRS-AND-INCLUS
• Nombre de lectures: 43
• Langue: English
• Poids de l'ouvrage: 5 Mo

Extrait

European Commission
ectorate General Health and Consumer Protection
European Commission
lirope Against Cancer Programme
Brussels-Luxembourg, 2000
.valuation and Monitoring of
Screening Pr
Europe Against Cancer onal Agency for European Network
European Commission Research on Cancer Cancer Registries
World Health Organization ir * -tr
ir it
itit'.
H it »
***
International Agency for European Network of Europe Against Cancer
Research onCancerCancer RegistriesEuropean Commission
World Heath Organisation
Evaluation and monitoring of
screening programmes
Edited by:
ι R. Sankila, E. Démaret, M. Hakarna, E. Lynge, L.J. Schouten, D.M. Parkin
for the European Network of Cancer Registries
European Commission
Europe Against Cancer Programme
Brussels­Luxembourg, 2000 A great deal of additional Information on the European Union is available on the Internet.
It can be accessed through the Europa server (httpVeuropa.eu.int).
Cataloguing data can be found at the end of this publication.
Luxembourg: Office for Official Publications of the European Communities, 2001
ISBN 92-894-0253-9
© European Communities, 2001
Reproduction is authorised provided the source is acknowledged.
Printed in Belgium Contents
Foreword
D. Byrne ν
List of contributorsvi
Chapter 1.Introduction:studydesign and the potential of cancerregistration
DMParkin1
Chapter 2.Planninganddesigning of screening programmes
M.Hakarna13
Chapter 3. Evaluation and monitoring of cancer screening: theoretical issues
S.Moss 29
Chapter4.Useofcancer registry data: prerequisites, limitationsandsolutions
J.A.A.M.van Dijck and L.J. Schouten 43
Chapter5.Evaluation and monitoringofscreeningforcervixcancer:timetrends
J.Smithand D.M. Parkin59
Chapter6.Cervixcancer: geographical correlations
A.Anttilaand E. Läärä77
Chapter 7. Cervix cancer: case­control studies
M. Zappa and S. Ciatto 99
Chapter 8. Cohort studiesevaluatingscreeningfor cervix cancer
E.Lynge119
Chapter 9. Cancer registries in evaluation of breast cancer screening programmes
S. Wait 133
Chapter10.Breastcancer: modelling of mortality trends
T.Hakulinen151
Chapter11.Screening for breast cancer: cohort studies
R. Sankila and E. Lynge 163
111 Chapter 12. Cancer registries in monitoring, evaluating and planning breast cancer
screening programmes
D. Stockton and J. McCann 181
Chapter 13. Population-based trends of prostate cancer in the United States before
and after widespread use of PSA
R.A. Stephenson 195
Chapter 14. Evaluation of screening for prostate cancer
F.E.Alexander 207
Chapter 15. Cancer registries in evaluation of screening for colorectal cancer
J. Faivre, A.M. Benhamiche and M.A. Tazi 213
Chapter 16. Cancer registries in early detection of cutaneous malignant melanoma
J.W.W. Coebergh and H.J. van der Rhee 22
Chapter 17. Lessons learned from neuroblastoma screening
R. Sankila 233
Chapter 18. Cancer registries and genetic screening
L. Tryggvadóttir 24
Chapter 19. Conclusions and recommendations
R. Sankila, L.J. Schouten and D.M. Parkin 26
IV Foreword
The European Commission considers it a priority to help in preventing death from cancer by early
detection through screening programmes. Thus the third action plan to combat cancer, better known as the
Europe against Cancer programme, has helped to provide evidence for European high quality cancer
screening programmes. A conditio sine qua non to establish and to monitor the efficacy of anyr g programme is the European-wide availability of high quality cancer registries, which is the
objective of the European Network of Cancer Registries (ENCR), another priority of the Europe against
Cancer programme.
While early detection of a specific cancer by screening appears, at first sight, to be a promising method of
preventing death, conclusive evidence on its efficacy at the public health level must first be established.
For cancer of the cervix uteri, for example, this was possible, using time trend analyses, based originally
on data from population-based cancer registries in the Nordic countries. For breast cancer screening using
mammography, the evidence of benefit is largely based on fairly small screening trials, and somewhat
varying results of population based time trend analyses. Overcoming these shortcomings became the
prime objective of the European Breast Cancer Screening Network, which has aided in establishing
European-wide guidelines for more uniform high quality breast cancer screening. In turn, this improved
the comparability of the available data from different national settings, demonstrating true European added
value.
It seems likely that new screening programmes will be implemented as public health policy based upon
limited screening trials, usually without a mechanism for evaluation of their effectiveness. However, it is
not self-evident that the positive results of screening trials will be replicated in a service setting, let alone
be readily transferable to other countries with different health care systems. In this instance, one of the
few tools available to evaluate the results of such new public health interventions is the population-based
cancer registry.
A number of factors may affect the efficacy of a screening intervention in the long term. There are
examples where the anticipated results of a newg policy were not achieved, but where, after
critical re-evaluation, the organisation of the programme was remodelled yielding satisfactory results. In
the era of evidence-based medicine, this routine monitoring of the performance of existing screening
programmes is of utmost importance. Population-based cancer registries are uniquely placed to provide
the data needed for these processes.
This monograph provides a wide range of experiences from cancer registries in Europe and North America
in the evaluation and monitoring of existing screening programmes. As such, I hope it will aid researchers
in choosing the necessary data and applying appropriate methods. The reader should also realise that
despite more than 30 years' experience, there are still very demanding aspects in the evaluation and
monitoring of screening programmes. These challenges need very careful consideration in each unique
setting.
David Byrne
Commissioner
Health and Consumer Protection Directorate-General
European Commission List of contributors
Dr Freda E. Alexander Dr Jan Willem Coebergh
Department of Public Health Services Comprehensive Cancer Centre South (IKZ)
The University of Edinburgh Zernikestraat 29
Medical School P.O.Box231
5600 AE Eindhoven Teviot Place
Edinburgh EH8 9AG, Scotland The Netherlands
United Kingdom
Mrs Eva Démaret
Dr Ahti Anttila Unit of Descriptive Epidemiology
Mass Screening Registry International Agency for Research on
Finnish Cancer y Cancer
150, cours Albert Thomas Liisankatu 21 Β
00170 Helsinki 69372 Lyon Cedex 08
Finland France
Dr Anne­Marie Benhamiche Dr Jean Faivre
Registre Bourguignon des Cancers Registre Bourguignon des Cancers Digestifs
Digestifs Faculté de Médecine
INSERM CRI 9505 7, Blvd Jeanne d'Arc
Faculté de Médecine 21033 Dijon Cedex
7, Blvd Jeanne d'Arc France
21033 Dijon Cedex
France Dr Timo Hakulinen
Finnish Cancer Registry
Dr Stefano Ciatto Institute for Statistical and Epidemiological
Centro per lo Studio e la Cancer Research
Liisankatu 21Β Prevenzione Oncologica
Viale A. Volta 171 00170 Helsinki 17
50131 Florence Finland
Italy
Dr Esa Läärä
University of Oulu
Department of Mathematical Sciences
P.O.Box 333
90571 Oulu
Finland
vi Dr Elsebeth Lynge Dr Leo J. Schouten
Institute of Public Health Maastricht Cancer Registry
University of Copenhagen Comprehensive Cancer Centre Limburg
Blegdamsvej 3 P.O.B0X 2208
2200 Copenhagen N 6201 HA Maastricht
Denmark The Netherlands
Dr Jenny McCann Dr Jenifer Smith
Department of Community Medicine South and West Cancer Intelligence Unit
University of Cambridge Highcroft, Romsey Road
Strangeways Research Laboratory Winchester S022 5DH
Wort's Causeway United Kingdom
Cambridge CB1 8RN
Dr Robert A. Stephenson United Kingdom
Department of Surgery
Dr Sue Moss University of Utah School of Medicine
Cancer Screening Evaluation Unit 50 North Medical Drive
Institute for Cancer Research Salt Lake City, UT 84132
D. Block, Cotswold Road USA
Sutton, Surrey SM2 5NG
United Kingdom Dr Diane Stockton
Cancer Surveillance Group
Dr D. Maxwell Parkin Scottish Cancer Intelligence Unit
Unit of Descriptive Epidemiology Information & Statistics Division
Trinity Park House, South Trinity Road International Agency for Research on
Cancer Edinburgh EH5 3SQ, Scotland
150, cours Albert Thomas United Kingdom
69372 Lyon Cedex 08
France Dr Mohammed A. Tazi
Registre Bourguignon des Cancers Digestifs
Dr Risto Sankila Faculté de Médecine
Unit of Descriptive Epidemiology 7, Blvd Jeanne d'Arc
International Agency for Research on 21033 Dijon
Cancer France
150, cours Alber